ArticleFrontiers in oncology2026
Immune checkpoint inhibitor-related intestinal pseudo-obstruction and multisystem immune-related adverse events in a post-gastrectomy patient: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors are increasingly recognized to be associated with multisystem immune-related adverse events. Cases presenting predominantly with intestinal pseudo-obstruction (IPO) are rare, prone to misdiagnosis, and may indicate broader immune-mediated toxicity. Case presentation: We report the case of a patient with gastric cancer who developed intestinal pseudo-obstruction and multisystem immune toxicity during postoperative adjuvant chemotherapy plus nivolumab. The patient's symptoms improved rapidly after glucocorticoid treatment. Conclusion: Immune checkpoint inhibitor-related intestinal pseudo-obstruction (irIPO) should be recognized early and diagnosed on the basis of a comprehensive clinical assessment. Differential diagnosis, multidisciplinary collaboration, and active screening for additional organ involvement are essential. Early glucocorticoid treatment may improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.